

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Treatment for acute bronchiolitis before and after implementation of new national guidelines: an observational study from primary and secondary care in Oslo, Norway

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2021-001111
Article Type:	Original research
Date Submitted by the Author:	29-Mar-2021
Complete List of Authors:	Klem, Nicolai; University of Oslo, Department of General Practice Skjerven, Håvard Ove; Oslo University Hospital Nilsen, Beate; Oslo Accident and Emergency Outpatient Clinic Brekke, Mette; University of Oslo, Department of General Practice Vällersnes, Odd Martin; University of Oslo, Department of General Practice
Keywords:	Health services research, Virology, Therapeutics

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Treatment for acute bronchiolitis before and after**
4
5
6 **implementation of new national guidelines: an observational study**
7
8
9 **from primary and secondary care in Oslo, Norway**
10
11
12
13
14
15
16
17

18 Nicolai Klem^{1,2}, Håvard Ove Skjerven³, Beate Nilsen¹, Mette Brekke⁴, Odd Martin

19
20 Vallersnes^{1,2}
21
22
23
24

25 **Affiliations:**

- 26
27 1. Oslo Accident and Emergency Outpatient Clinic, Department of Emergency General
28 Practice, City of Oslo Health Agency, Oslo, Norway
29
30 2. Department of General Practice, University of Oslo, Oslo, Norway
31
32 3. Department of Paediatrics, Oslo University Hospital, Oslo, Norway
33
34 4. General Practice Research Unit, University of Oslo, Oslo, Norway
35
36
37
38
39
40

41 **Address of correspondence to:**

42 Nicolai Klem, MD.

43
44 Oslo Accident and Emergency Outpatient Clinic, Department of Emergency General Practice,
45
46 City of Oslo Health Agency, Oslo, Norway
47
48

49 Falbesgate 18D, 0170 Oslo
50

51 E-mail: nicolaiklem@gmail.com, +47 92296568.
52
53
54
55
56
57
58
59

60 **Word count:** 2328

What is known about the subject

- Treatment guidelines for acute bronchiolitis no longer recommend the use of nebulized adrenaline
- Guidelines, often made in the specialist health services for specific conditions, are often perceived not to fit the primary care population

What this study adds

- The successful implementation of a new treatment guideline for acute bronchiolitis, reduced the use of nebulized adrenaline both in primary and secondary care
- An inverse rise in the use of nebulized saline was seen in both settings, though not specifically recommended
- Use of antibiotics remained low

ABSTRACT

Background: Acute bronchiolitis treatment guidelines changed in Norway in 2013, no longer recommending the use of nebulized adrenaline. We aimed to assess whether these changes were successfully implemented in both primary and secondary care. Secondary aims were to compare the difference in management of acute bronchiolitis patients in primary and secondary care between 2009 and 2017.

Methods: We retrospectively registered data on demographics, clinical features and management from electronic medical records of all infants (<12 months of age) diagnosed with acute bronchiolitis at a primary care centre (Oslo Accident and Emergency Outpatient Clinic) and a secondary care centre (Oslo University Hospital) in Norway in 2009, 2014, and 2017. All patient records were individually reviewed to ensure data accuracy.

Results: We included 680 (36.3%) patients from primary care and 1195 (63.7%) from secondary care. There was a reduction in the use of nebulized adrenaline from 2009 to 2017 from 66.9% to 16.1% of cases ($p<0.001$) in primary care and from 59.1 % to 4.9 % ($p<0.001$) in secondary care. In parallel, there was an increase in the use of nebulized saline treatment, from 0.8% to 53.8% ($p<0.001$) in primary care and from 39.3% to 65.3% ($p<0.001$) in secondary care. The decrease in the use of nebulized racemic adrenaline occurred earlier in secondary care than in primary care; 13.4 % vs 56.1%, respectively, in 2014.

Conclusions: Implementation of the new guidelines on the treatment of acute bronchiolitis were successfully implemented in both primary and secondary care.

Key words: Compliance, treatment guidelines, bronchiolitis, nebulizer treatment, racemic adrenaline, saline, RS-virus, antibiotic treatment, primary vs secondary care

INTRODUCTION

Bronchiolitis is an acute viral lower respiratory tract infection affecting infants below one year of age.(1) Multiple treatment options have been recommended and used throughout different regions and time periods, including nebulized beta-2-agonists, nebulized racemic adrenaline, systemic corticosteroids, antibiotics, and nebulized hypertonic saline.(1-4) Mecklin et al. showed that all of these options were used in infants below 12 months of age with bronchiolitis between 2000 and 2015 in Tampere, Finland, with an increasing use of nebulized hypertonic saline.(5) In 2013, nebulized racemic adrenaline was removed from the Norwegian national acute bronchiolitis treatment guidelines(6) as a consequence of the Bronchiolitis All-Study SE Norway that found no difference in patient outcomes in children given nebulized racemic adrenaline vs. children given nebulized saline.(2) In general, recently published guidelines from different regions recommend supportive care only and a minimal handling strategy in the treatment for acute bronchiolitis patients.(7-10)

Adherence to clinical guidelines in general practice has room for improvements.(11) One plausible explanation is that guidelines are often made by secondary care specialists for specific conditions that do not necessarily fit the primary care population.(12) The Norwegian guidelines for acute bronchiolitis are made by paediatricians for secondary care, but parts of the guidelines have been used also in Norwegian primary care.(6) To the best of our knowledge, no studies have compared how the same changes in a clinical guideline have been implemented in both primary and secondary care.

Aims

The primary aim of the study was to determine whether the new national treatment guidelines for acute bronchiolitis in Norway, published in 2013, were implemented in primary and

1
2
3 secondary care. Secondary aims were to compare the difference in management of acute
4
5 bronchiolitis patients in primary and secondary care between 2009 and 2017.
6
7
8
9
10

11 **METHODS**

12 **Study design**

13
14
15 A retrospective observational study of children < 12 months of age presenting with acute
16
17 bronchiolitis at the Oslo Accident and Emergency Outpatient Clinic (OAEOC) or at the Oslo
18
19 University Hospital, Division of Paediatric and Adolescent Medicine (OUH), in Oslo,
20
21 Norway, in 2009, 2014, and 2017.
22
23
24
25
26
27

28 **Settings**

29
30 The Norwegian healthcare system is two-tiered, with primary care holding a gate-keeping
31
32 function for secondary care. Unless triaged directly for hospital treatment by the ambulance
33
34 service, patients at all ages are assessed in primary care, usually by local family physicians
35
36 during office hours, or at primary care emergency outpatient clinics at weekends and nights. If
37
38 the primary care doctor decides that the patient needs secondary care, the patient is transferred
39
40 to hospital.
41
42
43
44
45

46
47 In Oslo, the main primary care emergency clinic is the OAEOC, open 24 hours a day, 365
48
49 days a year. Diagnostic and treatment resources include chest X-rays, point-of-care blood
50
51 tests, and nebulizer treatment. Oslo is the capital city of Norway and had 666 759 inhabitants
52
53 as per 1.1.2017.(13) The paediatric population (children < 18 years of age) in the OAEOC
54
55 catchment area was 137 233 as per 1.1.2017, while the OUH catchment area, covering 12 of
56
57 15 city districts, encompassed 110 958.(13)
58
59
60

Participants

We included all patients below the age of 12 months diagnosed with bronchiolitis at the OAEOC or the OUH from the 1st of January to the 31st of December of the three years 2009, 2014, and 2017.

At the OAEOC, eligible patients were identified from the patient registration lists in the electronic medical records. If the triage nurse had described airway illness as the presenting complain in a child below the age of 12 months, the case notes were reviewed by study personnel and the patient included if given a bronchiolitis diagnosis (R78 in the International Classification of Primary Care, 2nd edition (ICPC-2))(14) or treated for bronchiolitis with relevant bronchiolitis symptoms noted. At the OUH, all contacts involving patients below the age of 12 months with a diagnosis of bronchiolitis (J21 in the International Classification of Diseases and Related Health Problems (ICD-10))(15) were identified through an electronic search in the medical records. Electronic patient records for each acute admission were reviewed. In both settings, patients were included case by case, while planned follow-up contacts were excluded. Hence, one patient could be included several times as different cases.

We reviewed 5233 patient records at the OAEOC and 1520 at the OUH, yielding 680 included cases from the OAEOC and 1195 from the OUH.

Variables

We registered demographic data (gender, age), vital signs (heart rate, oxygen saturation, respiratory rate, temperature), and clinical signs of respiratory distress (retractions, cyanosis). Furthermore, we registered treatment given, including nebulized medication (racemic

1
2
3 adrenaline, saline, salbutamol), oxygen, high-flow nasal oxygen, ventilatory support
4
5 (continuous positive airway pressure (CPAP), bilevel positive airway pressure (BPAP),
6
7 respirator), nasogastric tube feeding, antipyretics, steroids, and antibiotics. Supplementary
8
9 investigations were also registered, including C-reactive protein (CRP), nasopharyngeal
10
11 swabs for virus and atypical bacterial agents, and chest X-rays. At the OAEOC, a CRP point-
12
13 of-care test was used, not measuring values < 5 mg/L, while the OUH used a laboratory CRP
14
15 test. Finally, we registered length of stay, whether the patient was transferred to hospital from
16
17 the OAEOC, whether nebulizer home treatment was initiated, and whether the patient re-
18
19 presented to the clinic within 48 hours.
20
21
22
23
24
25

26 **Statistical methods**

27
28 All data were analysed in IBM SPSS version 26 (IBM Corp., Chicago, IL). Pearson's chi-
29
30 square test was used to compare frequencies. For continuous data, one-way analysis of
31
32 variance (ANOVA) was used. Kruskal-Wallis test was used for the CRP data, which did not
33
34 follow the normal distribution. The significance level was set to 5 percent. Imputation for
35
36 missing data was not performed.
37
38
39
40
41

42 **Ethics**

43
44 The study was a quality improvement study, as per the Norwegian Law on Health Personnel
45
46 §26, retrospectively collecting anonymous data already registered in patient records.
47
48 Accordingly, the need for approval from an ethics committee was waived, as was the need to
49
50 obtain consent to participate. The study was approved by the Oslo University Hospital
51
52 Information Security and Privacy Office, and by the director of the Department of Emergency
53
54 General Practice at the City of Oslo Health Agency.
55
56
57
58
59
60

RESULTS

We included 680 cases from primary care and 1195 cases from secondary care. Mean age was higher in primary care than in secondary care, 6.1 months versus 4.8 months ($p < 0.001$). The gender distribution was similar, with 60.9 % boys in both settings. Clinical characteristics are shown in table 1.

There was a reduction in the use of nebulized racemic adrenaline treatment from 2009 to 2017; from 66.9 % (162/242) of cases to 16.1 % (32/199) ($p < 0.001$) in primary care and from 59.1 % (257/435) to 4.9 % (19/386) ($p < 0.001$) in secondary care (table 2).

Simultaneously, there was an increase in the use of nebulized saline treatment; from 0.8 % (2/242) to 53.8 % (107/199) ($p < 0.001$) in primary care and from 39.3 % (171/435) to 65.3 % (252/386) ($p < 0.001$) in secondary care. The decrease in the use of nebulized racemic adrenaline occurred earlier in secondary care (13.4 % (50/374) in 2014) than in primary care (56.1 % (134/239) in 2014).

In secondary care, there was also a reduction from 2009 to 2017 in the use of nebulized salbutamol from 14.5 % (63/435) of cases to 6.5 % (25/386) ($p = 0.001$), an increase in the use of oxygen supplement from 9.9 % (43/435) to 19.4 % (75/386) ($p < 0.001$), and of antipyretics from 6.2 % (27/435) to 13.0 % (50/386) ($p = 0.004$) (table 2). In-hospital antibiotic use was low throughout the study period; 1.9 % in 2009, 2.7 % in 2014 and 4.3 % in 2017 ($p = 0.136$). Antibiotic home-treatment initiated from the hospital was reduced from 4.6 % (20/435) to 2.8 % (11/386) ($p = 0.047$).

1
2
3 Furthermore, there was a decrease in the use of chest X-ray as a diagnostic tool, from 4.1 %
4 (10/242) to none ($p < 0.001$) in primary care and from 31.0 % (135/435) to 19.2 % (74/386)
5
6 (p < 0.001) in secondary care (table 2). At the hospital, microbiological tests were performed
7
8 in 72.6 % (867/1195) of the children. RS-virus was the main agent throughout, found in 69.3
9
10 % (601/867) of the samples (table 3).
11
12
13
14
15
16
17
18

19 **DISCUSSION**

20
21 In accordance with the guidelines published in 2013, the use of nebulized racemic adrenaline
22
23 was substantially reduced from 2009 to 2017 in both primary and secondary care. The change
24
25 occurred earlier (2014) in secondary than in primary care. In the same period, the use of
26
27 nebulized saline increased and antibiotics decreased in both settings. In hospital, the use of
28
29 oxygen and antipyretics increased.
30
31
32
33
34

35
36 The new treatment guidelines were implemented already in 2014 in secondary care and well
37
38 implemented in primary care in 2017. One can argue that this was fairly successful, as
39
40 implementation of guidelines are known to take time.(16, 17) Our results show slower
41
42 adaption to the guidelines in primary care than in secondary care. There is research suggesting
43
44 low adherence to guidelines in primary care,(11) which would support our findings. Primary
45
46 care physicians experience several barriers for adherence to guidelines, where lack of
47
48 awareness and lack of familiarity are the two most commonly reported.(18, 19) As physicians
49
50 in primary care manage patients of all ages with a wide spectrum of illnesses, the
51
52 implementation of guidelines for specific illnesses might not get general attention.(12) The
53
54 Bronchiolitis All-Study SE was conducted at the OUH previously to the guideline
55
56 implementation, directly involving most doctors and nurses attending the acute ward.(2, 20)
57
58
59
60

1
2
3 This would suggest a higher awareness and familiarity to the new guidelines at the hospital,
4 leading to faster adaptation. We consider full time employees and internal education programs
5
6 leading to faster adaptation. We consider full time employees and internal education programs
7
8 at both clinics crucial for successful implementation.
9

10
11
12 Apart from the primary care delay in implementing the new guidelines, we found similar
13
14 changes in the initial treatment of patients with acute bronchiolitis in primary and secondary
15
16 care. The increase in nebulized saline use is not evidence based and not recommended by
17
18 national guidelines. Overtreatment is an acknowledged challenge in medicine,(21) and there
19
20 is a possibility that the increasing use of nebulized saline is a consequence of the urge of
21
22 health care personnel to do something, by providing any specific therapy, rather than what
23
24 actually benefits the patients.
25
26
27
28
29

30
31 The reduction in the use of nebulized beta-2-agonists is supported by new guidelines and
32
33 research,(2, 9, 22-25) and is a focus across the world.(24, 25) Antibiotic treatment is not
34
35 recommended for acute bronchiolitis,(9, 26, 27) and overuse is a known problem.(28-30) Our
36
37 results showed a very low use of antibiotics, consistently below 5 %, compared to other
38
39 countries, where rates in the range of 3.5–11.1 % are reported.(28)
40
41
42
43
44

45 We found a steady rise in the use of highflow oxygen in the hospital setting. Recent research
46
47 has not clearly shown that this is beneficial for acute bronchiolitis treatment.(31, 32) Hospital
48
49 length of stay did not change during the study time period. However, there was an increase in
50
51 the proportion of patients discharged within 24 hours, from 49.9 % to 61.4 %, signifying that
52
53 a majority of hospital bronchiolitis patients only need a short period of supportive care.
54
55
56
57
58
59
60

1
2
3 No more than 40 % of the bronchiolitis patients at the OAEOC were sent on to secondary
4 care. This contribution to reducing hospital emergency department crowding is an advantage
5 of a gate keeping primary care emergency health service. The availability of nebulizer
6 treatment and short-term observation gives the OAEOC the capacity to treat and observe
7 children with a wide variety of airway symptoms, and hence better to identify the patients in
8 need of hospital treatment.
9
10
11
12
13
14
15
16
17
18

19 The main agent causing bronchiolitis is known to be RS-virus,(33, 34) as was the case in our
20 study, with Rhinovirus the second most common agent. Two or more agents were found in
21 more than one out of four children, less frequently than the 61% co-infections found by
22 Skjerven et al. in their review from 2016.(35) A relationship between viral findings and the
23 severity of respiratory disease in infants with acute bronchiolitis has not been established,
24 though it has been suggested that high genomic load can lead to longer hospital stay and more
25 use of oxygen and ventilatory support.(35, 36)
26
27
28
29
30
31
32
33
34
35
36
37

38 **Strengths and limitations**

39 Our study included a large patient population from both primary and secondary care.
40 Encompassing the two largest emergency departments for children in Oslo, our study
41 population is representative of the city population. Though patients were not included if
42 managed at other smaller primary care clinics, or referred by them or the ambulance service
43 directly to the neighbouring paediatric hospital covering the remaining 3 of 15 city districts,
44 this number is probably small and the population is most likely similar to ours. We therefore
45 consider our results to be representative for the population of children with acute bronchiolitis
46 needing primary and/or hospital care in Norway.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The medical journal of every study subject was thoroughly examined by the first author,
4
5 ensuring as complete and accurate data as possible.
6
7
8
9

10 Eligible patients were found retrospectively, and we sought to limit selection bias by having
11
12 clear and strict inclusion criteria. Still, some interpretation was necessary in the primary care
13
14 setting in cases where bronchiolitis had not been set as the main diagnosis and the patient was
15
16 included based on the case notes. Only the first author reviewed the patient records. This
17
18 secured a more consistent inclusion of patients, but at the same time carried the risk of
19
20 increased selection bias.
21
22
23
24
25

26 Since the inclusion of some patients was based on strict criteria from case notes, we may have
27
28 missed some patients in the primary care group receiving ICPC-2 symptoms diagnoses rather
29
30 than the specific diagnosis of acute bronchiolitis. This may also partly explain why the
31
32 number of included patients was lower at the OAEOC than the OUH. Furthermore, the
33
34 ambulance service brings severely sick patients directly to hospital, hence bypassing the
35
36 OAEOC.
37
38
39
40
41

42 **Conclusion**

43
44 There was a large and highly significant reduction in the use of nebulized racemic adrenaline
45
46 treatment after the introduction of new national guidelines in 2013, both in primary and
47
48 secondary health care. Simultaneously, there was an increase in the use of nebulized saline.
49
50 Implementation of the new guidelines occurred earlier in the hospital setting than in primary
51
52 care.
53
54
55
56
57
58
59
60

Acknowledgements

We thank the Department of Microbiology at the Oslo University Hospital for making the microbiological data available to us.

Funding statement

Dr Klem received a six months scholarship from the Norwegian Committee on Research in General Practice (Allmenntmedisinsk Forskningsutvalg (AFU)), a committee of the Norwegian College of General Practitioners.

Data sharing statement

Data are currently not available for sharing. Several manuscripts based on the data set are in preparation. Requests concerning the data may be sent to the corresponding author.

Authors' contributions

NK conceived and designed the study, collected and analysed the data, and drafted and revised the manuscript. HOS, MB, and BN contributed to designing the study and revised the manuscript. OMV contributed to designing the study, revised the manuscript, and supervised the project.

Competing interests:

The authors have no conflicts of interest to disclose.

Patient and public involvement

Patients were not involved in designing the study, but will be involved in disseminating the results to the wider patient community.

REFERENCES

1. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database Syst Rev* 2014(6):CD001266.
2. Skjerven HO, Hunderi JO, Brüggmann-Pieper SK, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. *N Engl J Med* 2013;368:2286-93.
3. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. *Pediatrics* 2010;125:342-9.
4. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. *Cochrane Database Syst Rev* 2013(6):CD004878.
5. Mecklin M, Heikkila P, Korppi M. The change in management of bronchiolitis in the intensive care unit between 2000 and 2015. *Eur J Pediatr* 2018;177:1131-7.
6. Norsk barnelegeforening. Akuttveileder i pediatri. <http://www.helsebiblioteket.no/retningslinjer/akuttveileder-i-pediatri/forside> (accessed 11 May 2017).
7. McNaughten B, Hart C, Shields M. Management of bronchiolitis in infants: key clinical questions. *Paediatr Child Health* 2017;27:324-7.
8. Everard ML, Hind D, Ugonna K, et al. Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review. *Health Technol Assess* 2015;19:1-130.
9. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics* 2014;134:e1474-502.

10. National Institute of Health and Care Excellence. NICE Guidelines 2015. Bronchiolitis in children diagnosis and management, 2015. <https://www.nice.org.uk/guidance/ng9> (accessed 11 May 2017).
11. Lugtenberg M, Burgers JS, Han D, et al. General practitioners' preferences for interventions to improve guideline adherence. *J Eval Clin Pract* 2014;20:820-6.
12. Austad B, Hetlevik I, Mjølstad BP, et al. Applying clinical guidelines in general practice: a qualitative study of potential complications. *BMC Fam Pract* 2016;17:92.
13. Oslo Municipality Statistics Database, 2017. <http://statistikkbanken.oslo.kommune.no/webview/index.jsp?catalog=http%3A%2F%2Fstatistikkbanken.oslo.kommune.no%3A80%2Fobj%2FfCatalog%2FCatalog48&submode=catalog&mode=documentation&top=yes> (accessed 11 Apr 2019).
14. World Health Organization. International Classification of Primary Care, 2nd ed. (ICPC-2). Geneva, 2003. <http://www.who.int/classifications/icd/adaptations/icpc2/en/> (accessed 11 May 2019).
15. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, 1992. <https://www.who.int/classifications/icd/en/bluebook.pdf> (accessed 11 May 2019).
16. Austad B, Hetlevik I, Bugten V, et al. Implementing guidelines for follow-up after surgery with ventilation tube in the tympanic membrane in Norway: a retrospective study. *BMC Ear Nose Throat Disord* 2013;13:5.
17. Aftab RA, Khan AH, Sulaiman SAS, et al. Does guideline knowledge affect treatment compliance among emergency doctors? *Am J Med Sci* 2014;348:357-61.
18. Lugtenberg M, Zegers-van Schaick JM, Westert GP, et al. Why don't physicians adhere to guideline recommendations in practice?: an analysis of barriers among Dutch general practitioners. *Implement Sci* 2009;4:54.

19. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines. *JAMA* 1999;282:1458-65.
20. Oymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants: a review. *Scand J Trauma Resusc Emerg Med* 2014;22:23.
21. Armstrong N. Overdiagnosis and overtreatment as a quality problem: insights from healthcare improvement research. *BMJ Qual Saf* 2018;27:571-5.
22. Hartling L, Fernandes RM, Bialy L, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. *BMJ* 2011;342:d1714.
23. Meissner HC. Viral bronchiolitis in children. *N Engl J Med* 2016;374:62-72.
24. Montejo M, Paniagua N, Saiz-Hernando C, et al. Initiatives to reduce treatments in bronchiolitis in the emergency department and primary care. *Arch Dis Child* 2021;106:294-300.
25. Oakley E, Brys T, Borland M, et al. Medication use in infants admitted with bronchiolitis. *Emerg Med Australas* 2018;30:389-97.
26. Friis B, Andersen P, Brenøe E, et al. Antibiotic treatment of pneumonia and bronchiolitis: a prospective randomised study. *Arch Dis Child* 1984;59:1038-45.
27. Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. *J Pediatr* 1988;113:266-71.
28. Zipursky A, Kuppermann N, Finkelstein Y, et al. International practice patterns of antibiotic therapy and laboratory testing in bronchiolitis. *Pediatrics* 2020;146:e20193684.
29. Lopez AA, Aslanova R, Bridger N, et al. Antibiotic use for inpatient bronchiolitis: did national guidelines impact practice at a pediatric hospital? *Hosp Pediatr* 2020;10:147-52.

- 1
2
3 30. Papenburg J, Fontela PS, Freitas RR, et al. Inappropriate antibiotic prescribing for acute
4
5 bronchiolitis in US emergency departments, 2007-2015. *J Pediatric Infect Dis Soc*
6
7 2019;8:567-70.
8
9
10 31. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen
11
12 therapy in infants with bronchiolitis. *N Engl J Med* 2018;378:1121-31.
13
14 32. Lin J, Zhang Y, Xiong L, et al. High-flow nasal cannula therapy for children with
15
16 bronchiolitis: a systematic review and meta-analysis. *Arch Dis Child* 2019;104:564-76.
17
18 33. Miron D, Srugo I, Kra-Oz Z, et al. Sole pathogen in acute bronchiolitis: is there a role for
19
20 other organisms apart from respiratory syncytial virus? *Pediatr Infect Dis J* 2010;29:e7-
21
22 e10.
23
24 34. Carlsen KH, Ørstavik I, Halvorsen K. Viral infections of the respiratory tract in
25
26 hospitalized children: a study from Oslo during a 90 months period. *Acta Paediatr Scand*
27
28 1983;72:53-8.
29
30 35. Skjerven HO, Megremis S, Papadopoulos NG, et al. Virus type and genomic load in acute
31
32 bronchiolitis: severity and treatment response with inhaled adrenaline. *J Infect Dis*
33
34 2016;213:915-21.
35
36 36. Wishaupt JO, van der Ploeg T, de Groot R, et al. Single- and multiple viral respiratory
37
38 infections in children: disease and management cannot be related to a specific pathogen.
39
40 *BMC Infect Dis* 2017;17:62.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics and clinical features of children treated for acute bronchiolitis in primary care and at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	Primary care ^b			Hospital ^b		
	2009 <i>n</i> = 242	2014 <i>n</i> = 239	2017 <i>n</i> = 199	2009 <i>n</i> = 435	2014 <i>n</i> = 374	2017 <i>n</i> = 386
Gender						
Girls (<i>n</i> (%))	99 (41.0)	91 (38.1)	76 (38.2)	180 (41.4)	142 (38.0)	145 (37.6)
Boys (<i>n</i> (%))	143 (59.0)	148 (61.9)	123 (61.8)	255 (58.6)	232 (62.0)	241 (62.4)
Age (months, mean ± SD)	6.4 ± 3.3	6.2 ± 3.4	5.7 ± 3.3	4.9 ± 3.1	5.0 ± 3.4	4.6 ± 3.2
Heart rate (per minute, mean ± SD)	152.6 ± 22.3	151.5 ± 37.4	155.0 ± 21.0	147.7 ± 19.4	148.1 ± 21.6	151.4 ± 19.1**
Respiratory rate (per minute, mean ± SD)	50.0 ± 12.0	49.2 ± 11.7	51.9 ± 11.3	50.7 ± 11.4	50.0 ± 11.1	48.4 ± 10.4*
Oxygen saturation (% , mean ± SD)	96.5 ± 3.0	96.0 ± 5.0	96.4 ± 2.8	97.1 ± 3	96.8 ± 3.9	97.1 ± 2.7
Retractions (<i>n</i> (%))	126 (52.1)	163 (68.2)	136 (68.3)*	253 (58.2)	197 (52.7)	237 (61.4)*
Cyanosis (<i>n</i> (%))	2 (0.8)	2 (0.8)	3 (1.5)	4 (0.9)	4 (1.1)	4 (1.0)
Temperature (°C, mean ± SD)	37.5 ± 0.9	37.4 ± 0.9	37.4 ± 0.9	37.7 ± 0.8	37.6 ± 0.8	37.5 ± 0.8*
CRP (mg/L, median (IQR)) ^a	10 (5–14)	6 (5–18.5)	5 (5–11.5)**	7.0 (1.5–17.6)	7.8 (1.7–20.6)	7.0 (1.4–18)

Comparisons were done across all three years at each setting: **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

^aCRP test used in primary care setting did not specify values < 5 mg/L. Values <5 mg/L are set as 5

^bExcept for two statistically significant changes in vital signs among the hospital patients; a rise in heart rate from 2009 to 2017; 147.7 ± 19.4 to 151.4 ± 19.1 (*p* < 0.01), and a fall in respiratory rate in the same time period; 50.7 ± 11.4 to 48.4 ± 10.4 (*p* < 0.05), there were no significant differences in vital signs or symptoms between the patient populations in the two settings, nor across the years at each setting.

CRP: C-reactive protein; IQR: interquartile range; SD: standard deviation.

Table 2. Management of children with acute bronchiolitis in primary care and at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	Primary care			Hospital		
	2009 <i>n</i> = 242	2014 <i>n</i> = 239	2017 <i>n</i> = 199	2009 <i>n</i> = 435	2014 <i>n</i> = 374	2017 <i>n</i> = 386
Nebulized racemic adrenaline (<i>n</i> (%))	162 (66.9)	134 (56.1)	32 (16.1)***	257 (59.1)	50 (13.4)	19 (4.9)***
Nebulized saline (<i>n</i> (%))	2 (0.8)	52 (21.8)	107 (53.8)***	171 (39.3)	278 (74.3)	252 (65.3)***
Nebulized salbutamol (<i>n</i> (%))	5 (2.1)	9 (3.8)	4 (2.0)	63 (14.5)	36 (9.6)	25 (6.5)**
Oxygen supplement (<i>n</i> (%))	5 (2.1)	4 (1.7)	4 (2.0)	43 (9.9)	86 (23.0)	75 (19.4)***
Betamethasone (<i>n</i> (%))	16 (6.6)	13 (5.4)	9 (4.5)	29 (6.7)	16 (4.3)	14 (3.6)
Antipyretics (<i>n</i> (%))	7 (2.9)	20 (8.4)	5 (2.5)**	27 (6.2)	34 (9.1)	50 (13.0)***
Chest X-ray (<i>n</i> (%))	10 (4.1)	0 (0.0)	0 (0.0)***	135 (31.0)	67 (17.9)	74 (19.2)***
Referral to hospital (<i>n</i> (%))	93 (38.4)	107 (44.8)	79 (39.7)	Not applicable		
Hospitalization days (<i>mean</i> ± <i>SD</i>)				2.7 ± 3.8	2.7 ± 3.0	2.2 ± 2.4
Hospitalized less than 24 hours (<i>n</i> (%))				217 (49.9)	197 (52.7)	237 (61.4)**
Highflow nasal oxygen (<i>n</i> (%))				0 (0.0)	20 (5.3)	38 (9.8)***
CPAP/BPAP (<i>n</i> (%))				19 (4.4)	27 (7.2)	23 (6.0)
Respirator/mechanical ventilation (<i>n</i> (%))	Not applicable			6 (1.4)	7 (1.9)	7 (1.8)
Nasogastric tube (<i>n</i> (%))				40 (9.2)	43 (11.5)	56 (14.5)
Microbiological nasopharyngeal testing				303 (69.7)	278 (74.3)	286 (74.1)
Antibiotics in hospital (<i>n</i> (%))				8 (1.9)	10 (2.7)	16 (4.3)
Antibiotics home treatment (<i>n</i> (%))	4 (1.7)	1 (0.4)	1 (0.5)	20 (4.6)	6 (1.6)	11 (2.8)*
Nebulization home-treatment (<i>n</i> (%))	Not applicable			227 (52.2)	231 (61.8)	238 (61.7)**
Recontact within 48 hours (<i>n</i> (%))	39 (16.1)	35 (14.6)	32 (16.1)	37 (8.5)	39 (10.4)	50 (13.0)

Comparisons were done across all three years at each setting: **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

BPAP: Bilevel positive airway pressure; CPAP: continuous positive airway pressure; SD: standard deviation.

Table 3 – Microbiological results from nasopharynx swabs in children with acute bronchiolitis treated at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	2009	2014	2017
	<i>n</i> = 303	<i>n</i> = 278	<i>n</i> = 286
RS-virus (<i>n</i> (%))	181 (59.7)	206 (74.1)	214 (74.8)
Rhinovirus (<i>n</i> (%))	^a	126 (45.3)	117 (40.9)
Other viruses (<i>n</i> (%))	63 (20.8)	78 (28.1)	73 (25.5)
Bacteria (<i>n</i> (%))	5 (1.7)	0 (0.0)	4 (1.4)
Two or more agents (<i>n</i> (%))	11 (3.6) ^a	79 (28.4)	56 (19.6)
Negative results (<i>n</i> (%))	87 (28.7) ^a	16 (5.8)	12 (4.2)

^aRhinovirus was not tested for in 2009.

RS-virus: Respiratory syncytial virus.

BMJ Paediatrics Open

Treatment for acute bronchiolitis before and after implementation of new national guidelines: a retrospective observational study from primary and secondary care in Oslo, Norway

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2021-001111.R1
Article Type:	Original research
Date Submitted by the Author:	30-Apr-2021
Complete List of Authors:	Klem, Nicolai; University of Oslo, Department of General Practice Skjerven, Håvard Ove; Oslo University Hospital Nilsen, Beate; Oslo Accident and Emergency Outpatient Clinic Brekke, Mette; University of Oslo, Department of General Practice Vallersnes, Odd Martin; University of Oslo, Department of General Practice
Keywords:	Health services research, Virology, Therapeutics

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Treatment for acute bronchiolitis before and after**
4
5
6 **implementation of new national guidelines: a retrospective**
7
8
9 **observational study from primary and secondary care in Oslo,**
10
11
12 **Norway**

13
14
15
16
17
18
19
20
21 Nicolai Klem^{1,2}, Håvard Ove Skjerven³, Beate Nilsen¹, Mette Brekke⁴, Odd Martin
22
23 Vallersnes^{1,2}
24
25

26
27 **Affiliations:**

- 28
29
30 1. Oslo Accident and Emergency Outpatient Clinic, Department of Emergency General
31
32 Practice, City of Oslo Health Agency, Oslo, Norway
33
34 2. Department of General Practice, University of Oslo, Oslo, Norway
35
36 3. Department of Paediatrics, Oslo University Hospital, Oslo, Norway
37
38 4. General Practice Research Unit, University of Oslo, Oslo, Norway
39
40
41
42
43
44

45 **Address of correspondence to:**

46 Nicolai Klem, MD.

47
48
49 Oslo Accident and Emergency Outpatient Clinic, Department of Emergency General Practice,
50
51 City of Oslo Health Agency, Oslo, Norway

52
53 Falbesgate 18D, 0170 Oslo

54
55
56 E-mail: nicolaiklem@gmail.com, +47 92296568.
57
58
59
60

1
2
3
4
5 **Word count:** 2395
6
7
8
9

10 **What is known about the subject**
11

- 12
- 13 • Treatment guidelines for acute bronchiolitis no longer recommend the use of
14 nebulized adrenaline
15
 - 16 • Guidelines, often made by hospital specialists for hospital care, are often perceived not
17 to fit the primary care population
18
19
20
21
22
23
24
25

26 **What this study adds**
27

- 28
- 29 • The successful implementation of a new treatment guideline for acute bronchiolitis,
30 reduced the use of nebulized adrenaline both in primary and secondary care
31
 - 32 • An inverse rise in the use of nebulized saline was seen in both settings, though not
33 specifically recommended
34
35
 - 36 • Use of antibiotics remained low
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Background: Acute bronchiolitis treatment guidelines changed in Norway in 2013, no longer recommending the use of nebulized adrenaline. We aimed to assess whether these changes were successfully implemented in both primary and secondary care. Secondary aims were to compare the difference in management of acute bronchiolitis patients in primary and secondary care between 2009 and 2017.

Methods: We retrospectively registered data on demographics, clinical features and management from electronic medical records of all infants (<12 months of age) diagnosed with acute bronchiolitis at a primary care centre (Oslo Accident and Emergency Outpatient Clinic) and a secondary care centre (Oslo University Hospital) in Norway in 2009, 2014, and 2017. All patient records were individually reviewed to ensure data accuracy.

Results: We included 680 (36.3%) patients from primary care and 1195 (63.7%) from secondary care. There was a reduction in the use of nebulized adrenaline from 2009 to 2017 from 66.9% to 16.1% of cases ($p<0.001$) in primary care and from 59.1 % to 4.9 % ($p<0.001$) in secondary care. In parallel, there was an increase in the use of nebulized saline treatment, from 0.8% to 53.8% ($p<0.001$) in primary care and from 39.3% to 65.3% ($p<0.001$) in secondary care. The decrease in the use of nebulized racemic adrenaline occurred earlier in secondary care than in primary care; 13.4 % vs 56.1%, respectively, in 2014.

Conclusions: Implementation of the new guidelines on the treatment of acute bronchiolitis were successfully implemented in both primary and secondary care.

Key words: Compliance, treatment guidelines, bronchiolitis, nebulizer treatment, racemic adrenaline, saline, RS-virus, antibiotic treatment, primary vs secondary care

INTRODUCTION

Bronchiolitis is an acute viral lower respiratory tract infection affecting infants below one year of age.(1) Multiple treatment options have been recommended and used throughout different regions and time periods, including nebulized beta-2-agonists, nebulized racemic adrenaline, systemic corticosteroids, antibiotics, and nebulized hypertonic saline.(1-4) Mecklin et al. showed that all of these options were used in infants below 12 months of age with bronchiolitis between 2000 and 2015 in Tampere, Finland, with an increasing use of nebulized hypertonic saline.(5) In 2013, nebulized racemic adrenaline was removed from the Norwegian national acute bronchiolitis treatment guidelines(6) as a consequence of the Bronchiolitis All-Study SE Norway that found no difference in patient outcomes in children given nebulized racemic adrenaline vs. children given nebulized saline.(2) In general, recently published guidelines from different regions recommend supportive care only and a minimal handling strategy in the treatment for acute bronchiolitis patients.(7-10)

Adherence to clinical guidelines in general practice has room for improvements.(11) One plausible explanation is that guidelines are often made by secondary care specialists for specific conditions that do not necessarily fit the primary care population.(12) The Norwegian guidelines for acute bronchiolitis are made by paediatricians for secondary care, but parts of the guidelines have been used also in Norwegian primary care.(6) To the best of our knowledge, no studies have compared how the same changes in a clinical guideline have been implemented in both primary and secondary care.

Aims

The primary aim of the study was to determine whether the new national treatment guidelines for acute bronchiolitis in Norway, published in 2013, were implemented in primary and secondary care. Secondary aims were to compare the difference in management of acute bronchiolitis patients in primary and secondary care between 2009 and 2017.

METHODS

Study design

A retrospective observational study of children < 12 months of age presenting with acute bronchiolitis at the Oslo Accident and Emergency Outpatient Clinic (OAEOC) or at the Oslo University Hospital, Division of Paediatric and Adolescent Medicine (OUH), in Oslo, Norway, in 2009, 2014, and 2017.

Settings

The Norwegian healthcare system is two-tiered, with primary care holding a gate-keeping function for secondary care. Unless triaged directly for hospital treatment by the ambulance service, patients at all ages are assessed in primary care, usually by local family physicians during office hours, or at primary care emergency outpatient clinics at weekends and nights. If the primary care doctor decides that the patient needs secondary care, the patient is transferred to hospital.

In Oslo, the main primary care emergency clinic is the OAEOC, open 24 hours a day, 365 days a year. Diagnostic and treatment resources include chest X-rays, point-of-care blood tests, and nebulizer treatment. Oslo is the capital city of Norway and had 666 759 inhabitants

1
2
3 as per 1.1.2017.(13) The paediatric population (children < 18 years of age) in the OAEOC
4
5 catchment area was 137 233 as per 1.1.2017, while the OUH catchment area, covering 12 of
6
7 15 city districts, encompassed 110 958.(13)
8
9

10 11 12 **Participants**

13
14 We included all patients below the age of 12 months diagnosed with bronchiolitis at the
15
16 OAEOC or the OUH from the 1st of January to the 31st of December of the three years 2009,
17
18 2014, and 2017.
19
20
21

22
23 At the OAEOC, eligible patients were identified from the patient registration lists in the
24
25 electronic medical records. If the triage nurse had described airway illness, or symptoms
26
27 associated with airway illness, as the presenting complaint in a child below the age of 12
28
29 months, the case notes were reviewed by study personnel and the patient included if given a
30
31 bronchiolitis diagnosis (R78 in the International Classification of Primary Care, 2nd edition
32
33 (ICPC-2))(14) or treated for bronchiolitis with relevant bronchiolitis symptoms noted. At the
34
35 OUH, all contacts involving patients below the age of 12 months with a diagnosis of
36
37 bronchiolitis (J21 in the International Classification of Diseases and Related Health Problems
38
39 (ICD-10))(15) were identified through an electronic search in the medical records. Electronic
40
41 patient records for each acute admission were reviewed. In both settings, patients were
42
43 included case by case, while planned follow-up contacts were excluded. Hence, one patient
44
45 could be included several times as different cases.
46
47
48
49
50
51

52
53 We reviewed 5233 patient records at the OAEOC and 1520 at the OUH, yielding 680
54
55 included cases from the OAEOC and 1195 from the OUH.
56
57
58
59
60

Variables

We registered demographic data (gender, age), vital signs (heart rate, oxygen saturation, respiratory rate, temperature), and clinical signs of respiratory distress (retractions, cyanosis). Furthermore, we registered treatment given, including nebulized medication (racemic adrenaline, saline, salbutamol), oxygen, high-flow nasal oxygen, ventilatory support (continuous positive airway pressure (CPAP), bilevel positive airway pressure (BPAP), respirator), nasogastric tube feeding, antipyretics, steroids, and antibiotics. Supplementary investigations were also registered, including C-reactive protein (CRP), nasopharyngeal swabs for virus and atypical bacterial agents, and chest X-rays. At the OAEOC, a CRP point-of-care test was used, not measuring values < 5 mg/L, while the OUH used a laboratory CRP test. Finally, we registered length of stay, whether the patient was transferred to hospital from the OAEOC, whether nebulizer home treatment was initiated, and whether the patient re-presented to the clinic within 48 hours.

Statistical methods

All data were analysed in IBM SPSS version 26 (IBM Corp., Chicago, IL). Pearson's chi-square test was used to compare frequencies. For continuous data, one-way analysis of variance (ANOVA) was used. Kruskal-Wallis test was used for the CRP data, which did not follow the normal distribution. The significance level was set to 5 percent. Imputation for missing data was not performed.

Ethics

The study was a quality improvement study, as per the Norwegian Law on Health Personnel §26, retrospectively collecting anonymous data already registered in patient records.

Accordingly, the need for approval from an ethics committee was waived, as was the need to

1
2
3 obtain consent to participate. The study was approved by the Oslo University Hospital
4
5 Information Security and Privacy Office, and by the director of the Department of Emergency
6
7 General Practice at the City of Oslo Health Agency.
8
9
10

11 12 13 14 **RESULTS**

15
16 We included 680 cases from primary care and 1195 cases from secondary care. Mean age was
17
18 higher in primary care than in secondary care, 6.1 months versus 4.8 months ($p < 0.001$). The
19
20 gender distribution was similar, with 60.9 % boys in both settings. Clinical characteristics are
21
22 shown in table 1.
23
24
25

26
27
28 There was a reduction in the use of nebulized racemic adrenaline treatment from 2009 to
29
30 2017; from 66.9 % (162/242) of cases to 16.1 % (32/199) ($p < 0.001$) in primary care and
31
32 from 59.1 % (257/435) to 4.9 % (19/386) ($p < 0.001$) in secondary care (table 2).
33
34

35
36 Simultaneously, there was an increase in the use of nebulized saline treatment; from 0.8 %
37
38 (2/242) to 53.8 % (107/199) ($p < 0.001$) in primary care and from 39.3 % (171/435) to 65.3 %
39
40 (252/386) ($p < 0.001$) in secondary care. The decrease in the use of nebulized racemic
41
42 adrenaline occurred earlier in secondary care (13.4 % (50/374) in 2014) than in primary care
43
44 (56.1 % (134/239) in 2014).
45
46
47

48
49 In secondary care, there was also a reduction from 2009 to 2017 in the use of nebulized
50
51 salbutamol from 14.5 % (63/435) of cases to 6.5 % (25/386) ($p = 0.001$), an increase in the
52
53 use of oxygen supplement from 9.9 % (43/435) to 19.4 % (75/386) ($p < 0.001$), and of
54
55 antipyretics from 6.2 % (27/435) to 13.0 % (50/386) ($p = 0.004$) (table 2). In-hospital
56
57 antibiotic use was low throughout the study period; 1.9 % in 2009, 2.7 % in 2014 and 4.3 %
58
59
60

1
2
3 in 2017 ($p = 0.136$). Antibiotic home-treatment initiated from the hospital was reduced from
4
5 4.6 % (20/435) to 2.8 % (11/386) ($p = 0.047$).
6
7

8
9
10 Furthermore, there was a decrease in the use of chest X-ray as a diagnostic tool, from 4.1 %
11
12 (10/242) to none ($p < 0.001$) in primary care and from 31.0 % (135/435) to 19.2 % (74/386)
13
14 ($p < 0.001$) in secondary care (table 2). At the hospital, microbiological tests were performed
15
16 in 72.6 % (867/1195) of the children. RS-virus was the main agent throughout, found in 69.3
17
18 % (601/867) of the samples (table 3).
19
20
21
22
23
24
25

26 **DISCUSSION**

27
28 In accordance with the guidelines published in 2013, the use of nebulized racemic adrenaline
29
30 was substantially reduced from 2009 to 2017 in both primary and secondary care. The change
31
32 occurred earlier (2014) in secondary than in primary care. In the same period, the use of
33
34 nebulized saline increased and antibiotics decreased in both settings. In hospital, the use of
35
36 oxygen and antipyretics increased.
37
38
39
40
41

42 The new treatment guidelines were implemented already in 2014 in secondary care and well
43
44 implemented in primary care in 2017. One can argue that this was fairly successful, as
45
46 implementation of guidelines are known to take time.(16, 17) Our results show slower
47
48 adaption to the guidelines in primary care than in secondary care. There is research suggesting
49
50 lower adherence to guidelines in primary care,(11) which would support our findings. Primary
51
52 care physicians experience several barriers for adherence to guidelines, where lack of
53
54 awareness and lack of familiarity are the two most commonly reported.(18, 19) As physicians
55
56 in primary care manage patients of all ages with a wide spectrum of illnesses, the
57
58
59
60

1
2
3 implementation of guidelines for specific illnesses might not get general attention.(12) The
4
5 Bronchiolitis All-Study SE was conducted at the OUH previously to the guideline
6
7 implementation, directly involving most doctors and nurses attending the acute ward.(2, 20)
8
9
10 This would suggest a higher awareness and familiarity to the new guidelines at the hospital,
11
12 leading to faster adaptation. We consider full time employees and internal education programs
13
14 at both clinics crucial for successful implementation.
15
16
17
18

19
20 Apart from the primary care delay in implementing the new guidelines, we found similar
21
22 changes in the initial treatment of patients with acute bronchiolitis in primary and secondary
23
24 care. The increase in nebulized saline use is not evidence based and not recommended by
25
26 national guidelines. Overtreatment is an acknowledged challenge in medicine,(21) and there
27
28 is a possibility that the increasing use of nebulized saline is a consequence of the urge of
29
30 health care personnel to do something, by providing any specific therapy rather than what is
31
32 evidence based management.
33
34
35
36
37

38
39 The reduction in the use of nebulized beta-2-agonists is supported by new guidelines and
40
41 research,(2, 9, 22-25) and is a focus across the world.(24, 25) Antibiotic treatment is not
42
43 recommended for acute bronchiolitis,(9, 26, 27) and overuse is a known problem.(28-30) Our
44
45 results showed a very low use of antibiotics, consistently below 5 %, compared to other
46
47 countries, where rates in the range of 3.5–11.1 % are reported.(28)
48
49
50

51
52 We found a steady rise in the use of highflow oxygen in the hospital setting. Recent research
53
54 has not clearly shown that this is beneficial for acute bronchiolitis treatment.(31, 32) Hospital
55
56 length of stay did not change during the study time period. However, there was an increase in
57
58
59
60

1
2
3 the proportion of patients discharged within 24 hours, from 49.9 % to 61.4 %, signifying that
4 a majority of hospital bronchiolitis patients only need a short period of supportive care.
5
6
7
8
9

10 No more than 40 % of the bronchiolitis patients at the OAEOC were sent on to secondary
11 care. This contribution to reducing hospital emergency department crowding is an advantage
12 of a gate keeping primary care emergency health service. The availability of nebulizer
13 treatment and short-term observation gives the OAEOC the capacity to treat and observe
14 children with a wide variety of airway symptoms, and hence better to identify the patients in
15 need of hospital treatment.
16
17
18
19
20
21
22
23
24
25

26 The main agent causing bronchiolitis is known to be RS-virus,(33, 34) as was the case in our
27 study, with Rhinovirus the second most common agent. Two or more agents were found in
28 more than one out of four children, less frequently than the 61% co-infections found by
29 Skjerven et al. in their review from 2016.(35) A relationship between viral findings and the
30 severity of respiratory disease in infants with acute bronchiolitis has not been established,
31 though it has been suggested that high genomic load can lead to longer hospital stay and more
32 use of oxygen and ventilatory support.(35, 36)
33
34
35
36
37
38
39
40
41
42
43
44

45 **Strengths and limitations**

46 Our study included a large patient population from both primary and secondary care.
47 Encompassing the two largest emergency departments for children in Oslo, our study
48 population is representative of the city population. Though patients were not included if
49 managed at other smaller primary care clinics, or referred by them or the ambulance service
50 directly to the neighbouring paediatric hospital covering the remaining 3 of 15 city districts,
51 this number is probably small and the population is most likely similar to ours. We therefore
52
53
54
55
56
57
58
59
60

1
2
3 consider our results to be representative for the population of children with acute bronchiolitis
4
5 needing primary and/or hospital care in Norway.
6
7
8
9

10 The medical journal of every study subject was thoroughly examined by the first author,
11 ensuring as complete and accurate data as possible. Clinical signs, diagnostic investigations,
12 or treatments not mentioned in the patient records were considered not present or not
13 performed. This may have resulted in some underreporting, though not enough to have an
14 impact on our conclusions.
15
16
17
18
19
20
21
22

23 Eligible patients were found retrospectively, and we sought to limit selection bias by having
24 clear and strict inclusion criteria. Still, some interpretation was necessary in the primary care
25 setting in cases where bronchiolitis had not been set as the main diagnosis and the patient was
26 included based on the case notes. Only the first author reviewed the patient records. This
27 secured a more consistent inclusion of patients, but at the same time carried the risk of
28 increased selection bias.
29
30
31
32
33
34
35
36
37
38
39

40 Since the inclusion of some patients was based on strict criteria from case notes, we may have
41 missed some patients in the primary care group receiving ICPC-2 symptoms diagnoses rather
42 than the specific diagnosis of acute bronchiolitis. However, the patient records of all
43 individuals with related symptom diagnoses was manually screened to identify signs and
44 symptoms in order to identify acute bronchiolitis. This may also partly explain why the
45 number of included patients was lower at the OAEOC than the OUH. Furthermore, the
46 ambulance service brings severely sick patients directly to hospital, hence bypassing the
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Conclusion

There was a large and highly significant reduction in the use of nebulized racemic adrenaline treatment after the introduction of new national guidelines in 2013, both in primary and secondary health care. Simultaneously, there was an increase in the use of nebulized saline. Implementation of the new guidelines occurred earlier in the hospital setting than in primary care.

Acknowledgements

We thank the Department of Microbiology at the Oslo University Hospital for making the microbiological data available to us.

Funding statement

Dr Klem received a six months scholarship from the Norwegian Committee on Research in General Practice (Allmenntmedisinsk Forskningsutvalg (AFU)), a committee of the Norwegian College of General Practitioners.

Data sharing statement

Data are currently not available for sharing. Several manuscripts based on the data set are in preparation. Requests concerning the data may be sent to the corresponding author.

Authors' contributions

NK conceived and designed the study, collected and analysed the data, and drafted and revised the manuscript. HOS, MB, and BN contributed to designing the study and revised the

1
2
3 manuscript. OMV contributed to designing the study, revised the manuscript, and supervised
4 the project.
5
6
7
8
9

10 **Competing interests:**

11
12 The authors have no conflicts of interest to disclose.
13
14
15
16

17 **Patient and public involvement**

18
19 Patients were not involved in designing the study, but will be involved in disseminating the
20 results to the wider patient community.
21
22
23
24
25

26 **REFERENCES**

- 27
28 1. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database Syst*
29 *Rev* 2014(6):CD001266.
30
31
- 32
33 2. Skjerven HO, Hunderi JO, Brüggmann-Pieper SK, et al. Racemic adrenaline and inhalation
34 strategies in acute bronchiolitis. *N Engl J Med* 2013;368:2286-93.
35
36
- 37
38 3. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management.
39
40 *Pediatrics* 2010;125:342-9.
41
- 42
43 4. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral
44 bronchiolitis in infants and young children. *Cochrane Database Syst Rev*
45 2013(6):CD004878.
46
47
- 48
49 5. Mecklin M, Heikkila P, Korppi M. The change in management of bronchiolitis in the
50 intensive care unit between 2000 and 2015. *Eur J Pediatr* 2018;177:1131-7.
51
52
- 53
54 6. Norsk barnelegeforening. Akuttveileder i pediatri.
55
56 <http://www.helsebiblioteket.no/retningslinjer/akuttveileder-i-pediatri/forside> (accessed 11
57
58 May 2017).
59
60

- 1
2
3 7. McNaughten B, Hart C, Shields M. Management of bronchiolitis in infants: key clinical
4 questions. *Paediatr Child Health* 2017;27:324-7.
5
6
- 7
8 8. Everard ML, Hind D, Ugonna K, et al. Saline in acute bronchiolitis RCT and economic
9 evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and
10 systematic review. *Health Technol Assess* 2015;19:1-130.
11
12
- 13
14 9. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis,
15 management, and prevention of bronchiolitis. *Pediatrics* 2014;134:e1474-502.
16
17
- 18
19 10. National Institute of Health and Care Excellence. NICE Guidelines 2015. Bronchiolitis in
20 children diagnosis and management, 2015. <https://www.nice.org.uk/guidance/ng9>
21 (accessed 11 May 2017).
22
23
- 24
25 11. Lugtenberg M, Burgers JS, Han D, et al. General practitioners' preferences for
26 interventions to improve guideline adherence. *J Eval Clin Pract* 2014;20:820-6.
27
28
- 29
30 12. Austad B, Hetlevik I, Mjølstad BP, et al. Applying clinical guidelines in general practice:
31 a qualitative study of potential complications. *BMC Fam Pract* 2016;17:92.
32
33
- 34
35 13. Oslo Municipality Statistics Database, 2017.
36
37 <http://statistikkbanken.oslo.kommune.no/webview/index.jsp?catalog=http%3A%2F%2Fstatistikkbanken.oslo.kommune.no%3A80%2Fobj%2FfCatalog%2FCatalog48&submode=catalog&mode=documentation&top=yes> (accessed 11 Apr 2019).
38
39
40
41
42
43
- 44
45 14. World Health Organization. International Classification of Primary Care, 2nd ed. (ICPC-
46 2). Geneva, 2003. <http://www.who.int/classifications/icd/adaptations/icpc2/en/> (accessed
47 11 May 2019).
48
49
- 50
51 15. World Health Organization. The ICD-10 classification of mental and behavioural
52 disorders: clinical descriptions and diagnostic guidelines. Geneva, 1992.
53
54
55
56 <https://www.who.int/classifications/icd/en/bluebook.pdf> (accessed 11 May 2019).
57
58
59
60

16. Austad B, Hetlevik I, Bugten V, et al. Implementing guidelines for follow-up after surgery with ventilation tube in the tympanic membrane in Norway: a retrospective study. *BMC Ear Nose Throat Disord* 2013;13:5.
17. Aftab RA, Khan AH, Sulaiman SAS, et al. Does guideline knowledge affect treatment compliance among emergency doctors? *Am J Med Sci* 2014;348:357-61.
18. Lugtenberg M, Zegers-van Schaick JM, Westert GP, et al. Why don't physicians adhere to guideline recommendations in practice?: an analysis of barriers among Dutch general practitioners. *Implement Sci* 2009;4:54.
19. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines. *JAMA* 1999;282:1458-65.
20. Oymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants: a review. *Scand J Trauma Resusc Emerg Med* 2014;22:23.
21. Armstrong N. Overdiagnosis and overtreatment as a quality problem: insights from healthcare improvement research. *BMJ Qual Saf* 2018;27:571-5.
22. Hartling L, Fernandes RM, Bialy L, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. *BMJ* 2011;342:d1714.
23. Meissner HC. Viral bronchiolitis in children. *N Engl J Med* 2016;374:62-72.
24. Montejo M, Paniagua N, Saiz-Hernando C, et al. Initiatives to reduce treatments in bronchiolitis in the emergency department and primary care. *Arch Dis Child* 2021;106:294-300.
25. Oakley E, Brys T, Borland M, et al. Medication use in infants admitted with bronchiolitis. *Emerg Med Australas* 2018;30:389-97.
26. Friis B, Andersen P, Brenøe E, et al. Antibiotic treatment of pneumonia and bronchiolitis: a prospective randomised study. *Arch Dis Child* 1984;59:1038-45.

- 1
2
3 27. Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants
4 hospitalized with respiratory syncytial viral infection. *J Pediatr* 1988;113:266-71.
5
6
7
8 28. Zipursky A, Kuppermann N, Finkelstein Y, et al. International practice patterns of
9 antibiotic therapy and laboratory testing in bronchiolitis. *Pediatrics* 2020;146:e20193684.
10
11
12 29. Lopez AA, Aslanova R, Bridger N, et al. Antibiotic use for inpatient bronchiolitis: did
13 national guidelines impact practice at a pediatric hospital? *Hosp Pediatr* 2020;10:147-52.
14
15
16 30. Papenburg J, Fontela PS, Freitas RR, et al. Inappropriate antibiotic prescribing for acute
17 bronchiolitis in US emergency departments, 2007-2015. *J Pediatric Infect Dis Soc*
18 2019;8:567-70.
19
20
21
22 31. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen
23 therapy in infants with bronchiolitis. *N Engl J Med* 2018;378:1121-31.
24
25
26
27 32. Lin J, Zhang Y, Xiong L, et al. High-flow nasal cannula therapy for children with
28 bronchiolitis: a systematic review and meta-analysis. *Arch Dis Child* 2019;104:564-76.
29
30
31
32 33. Miron D, Srugo I, Kra-Oz Z, et al. Sole pathogen in acute bronchiolitis: is there a role for
33 other organisms apart from respiratory syncytial virus? *Pediatr Infect Dis J* 2010;29:e7-
34 e10.
35
36
37
38 34. Carlsen KH, Ørstavik I, Halvorsen K. Viral infections of the respiratory tract in
39 hospitalized children: a study from Oslo during a 90 months period. *Acta Paediatr Scand*
40 1983;72:53-8.
41
42
43
44 35. Skjerven HO, Megremis S, Papadopoulos NG, et al. Virus type and genomic load in acute
45 bronchiolitis: severity and treatment response with inhaled adrenaline. *J Infect Dis*
46 2016;213:915-21.
47
48
49
50 36. Wishaupt JO, van der Ploeg T, de Groot R, et al. Single- and multiple viral respiratory
51 infections in children: disease and management cannot be related to a specific pathogen.
52 *BMC Infect Dis* 2017;17:62.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Table 1. Demographics and clinical features of children treated for acute bronchiolitis in primary care and at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	Primary care ^b			Hospital ^b		
	2009 <i>n</i> = 242	2014 <i>n</i> = 239	2017 <i>n</i> = 199	2009 <i>n</i> = 435	2014 <i>n</i> = 374	2017 <i>n</i> = 386
Gender						
Girls (<i>n</i> (%))	99 (41.0)	91 (38.1)	76 (38.2)	180 (41.4)	142 (38.0)	145 (37.6)
Boys (<i>n</i> (%))	143 (59.0)	148 (61.9)	123 (61.8)	255 (58.6)	232 (62.0)	241 (62.4)
Age (months, mean ± SD)	6.4 ± 3.3	6.2 ± 3.4	5.7 ± 3.3	4.9 ± 3.1	5.0 ± 3.4	4.6 ± 3.2
Heart rate (per minute, mean ± SD)	152.6 ± 22.3	151.5 ± 37.4	155.0 ± 21.0	147.7 ± 19.4	148.1 ± 21.6	151.4 ± 19.1**
Respiratory rate (per minute, mean ± SD)	50.0 ± 12.0	49.2 ± 11.7	51.9 ± 11.3	50.7 ± 11.4	50.0 ± 11.1	48.4 ± 10.4*
Oxygen saturation (% , mean ± SD)	96.5 ± 3.0	96.0 ± 5.0	96.4 ± 2.8	97.1 ± 3	96.8 ± 3.9	97.1 ± 2.7
Retractions (<i>n</i> (%))	126 (52.1)	163 (68.2)	136 (68.3)*	253 (58.2)	197 (52.7)	237 (61.4)*
Cyanosis (<i>n</i> (%))	2 (0.8)	2 (0.8)	3 (1.5)	4 (0.9)	4 (1.1)	4 (1.0)
Temperature (°C, mean ± SD)	37.5 ± 0.9	37.4 ± 0.9	37.4 ± 0.9	37.7 ± 0.8	37.6 ± 0.8	37.5 ± 0.8*
CRP (mg/L, median (IQR)) ^a	10 (5–14)	6 (5–18.5)	5 (5–11.5)**	7.0 (1.5–17.6)	7.8 (1.7–20.6)	7.0 (1.4–18)

Comparisons were done across all three years at each setting: **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

^aCRP test used in primary care setting did not specify values < 5 mg/L. Values <5 mg/L are set as 5

^bExcept for two statistically significant changes in vital signs among the hospital patients; a rise in heart rate from 2009 to 2017; 147.7 ± 19.4 to 151.4 ± 19.1 (*p* < 0.01), and a fall in respiratory rate in the same time period; 50.7 ± 11.4 to 48.4 ± 10.4 (*p* < 0.05), there were no significant differences in vital signs or symptoms between the patient populations in the two settings, nor across the years at each setting.

CRP: C-reactive protein; IQR: interquartile range; SD: standard deviation.

Table 2. Management of children with acute bronchiolitis in primary care and at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	Primary care			Hospital		
	2009 <i>n</i> = 242	2014 <i>n</i> = 239	2017 <i>n</i> = 199	2009 <i>n</i> = 435	2014 <i>n</i> = 374	2017 <i>n</i> = 386
Nebulized racemic adrenaline (<i>n</i> (%))	162 (66.9)	134 (56.1)	32 (16.1)***	257 (59.1)	50 (13.4)	19 (4.9)***
Nebulized saline (<i>n</i> (%))	2 (0.8)	52 (21.8)	107 (53.8)***	171 (39.3)	278 (74.3)	252 (65.3)***
Nebulized salbutamol (<i>n</i> (%))	5 (2.1)	9 (3.8)	4 (2.0)	63 (14.5)	36 (9.6)	25 (6.5)**
Oxygen supplement (<i>n</i> (%))	5 (2.1)	4 (1.7)	4 (2.0)	43 (9.9)	86 (23.0)	75 (19.4)***
Betamethasone (<i>n</i> (%))	16 (6.6)	13 (5.4)	9 (4.5)	29 (6.7)	16 (4.3)	14 (3.6)
Antipyretics (<i>n</i> (%))	7 (2.9)	20 (8.4)	5 (2.5)**	27 (6.2)	34 (9.1)	50 (13.0)***
Chest X-ray (<i>n</i> (%))	10 (4.1)	0 (0.0)	0 (0.0)***	135 (31.0)	67 (17.9)	74 (19.2)***
Referral to hospital (<i>n</i> (%))	93 (38.4)	107 (44.8)	79 (39.7)	Not applicable		
Hospitalization days (<i>mean</i> ± <i>SD</i>)				2.7 ± 3.8	2.7 ± 3.0	2.2 ± 2.4
Hospitalized less than 24 hours (<i>n</i> (%))				217 (49.9)	197 (52.7)	237 (61.4)**
Highflow nasal oxygen (<i>n</i> (%))				0 (0.0)	20 (5.3)	38 (9.8)***
CPAP/BPAP (<i>n</i> (%))				19 (4.4)	27 (7.2)	23 (6.0)
Respirator/mechanical ventilation (<i>n</i> (%))	Not applicable			6 (1.4)	7 (1.9)	7 (1.8)
Nasogastric tube (<i>n</i> (%))				40 (9.2)	43 (11.5)	56 (14.5)
Microbiological nasopharyngeal testing				303 (69.7)	278 (74.3)	286 (74.1)
Antibiotics in hospital (<i>n</i> (%))				8 (1.9)	10 (2.7)	16 (4.3)
Antibiotics home treatment (<i>n</i> (%))	4 (1.7)	1 (0.4)	1 (0.5)	20 (4.6)	6 (1.6)	11 (2.8)*
Nebulization home-treatment (<i>n</i> (%))	Not applicable			227 (52.2)	231 (61.8)	238 (61.7)**
Recontact within 48 hours (<i>n</i> (%))	39 (16.1)	35 (14.6)	32 (16.1)	37 (8.5)	39 (10.4)	50 (13.0)

Comparisons were done across all three years at each setting: **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

BPAP: Bilevel positive airway pressure; CPAP: continuous positive airway pressure; SD: standard deviation.

Table 3 – Microbiological results from nasopharynx swabs in children with acute bronchiolitis treated at hospital in Oslo, Norway, before and after introduction of new treatment guidelines in 2013

	2009	2014	2017
	<i>n</i> = 303	<i>n</i> = 278	<i>n</i> = 286
RS-virus (<i>n</i> (%))	181 (59.7)	206 (74.1)	214 (74.8)
Rhinovirus (<i>n</i> (%))	^a	126 (45.3)	117 (40.9)
Other viruses (<i>n</i> (%))	63 (20.8)	78 (28.1)	73 (25.5)
Bacteria (<i>n</i> (%))	5 (1.7)	0 (0.0)	4 (1.4)
Two or more agents (<i>n</i> (%))	11 (3.6) ^a	79 (28.4)	56 (19.6)
Negative results (<i>n</i> (%))	87 (28.7) ^a	16 (5.8)	12 (4.2)

^aRhinovirus was not tested for in 2009.

RS-virus: Respiratory syncytial virus.